Psilocybin: a psychedelic alternative to antidepressants?
Pharmaceutical journal/The pharmaceutical journal 2022 DOI: 10.1211/pj.2022.1.169269 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Randomized controlled trial Peer reviewed |
|---|---|
| Population | People with treatment-resistant depression |
| Intervention | Psilocybin |
| Dose | 25 mg |
| Duration | 12-week follow-up |
| Topics | Psilocybin |
| Keywords | Hallucinogen Pharmacology |
| Key findings | A single 25mg dose of psilocybin with psychological support improved symptoms of treatment-resistant depression for up to 12 weeks. |
Abstract
In November 2022, the largest trial to date of the psychedelic drug, psilocybin, showed that — alongside psychological support — a single 25mg dose could improve the symptoms of treatment-resistant depression for up to 12 weeks. Previous studies have suggested an antidepressant mechanism for psilocybin therapy and have shown that psilocybin is at least as […]